This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stoica, A. Articles by Martin, M. B. Search for Related Content PubMed PubMed Citation Articles by Stoica, A. Articles by Martin, M. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Breast Cancer Hazardous Substances DB ESTRADIOL

Effects of Arsenite on Estrogen Receptor- Expression and Activity in MCF-7 Breast Cancer Cells¹

Department of Biochemistry and Molecular Biology, Lombardi Cancer Center, Georgetown University, Washington, D.C. 20007

Address all correspondence and requests for reprints to: Dr. Mary Beth Martin, Lombardi Cancer Center, E411 Research Building, 3970 Reservoir Road NW, Washington, D.C. 20007. E-mail: martinmb{at}gunet.georgetown.edu

To determine whether arsenite has estrogen-like activities, the effects of this compound on estrogen receptor- (ER) and other estrogen-regulated genes were measured in the human breast cancer cell line MCF-7. Treatment of cells with 1 µM arsenite resulted in a 60% decrease in the amount of ER and in a parallel decrease of 40% in ER messenger RNA. Progesterone receptor concentration increased 22-fold after arsenite treatment. pS2 messenger RNA also increased 2.1-fold after treatment. The induction of progesterone receptor and pS2 was blocked by the antiestrogen ICI-182,780. In transient cotransfection experiments of wild-type ER and an estrogen response element-reporter construct, arsenite stimulated chloramphenicol acetyltransferase (CAT) activity. In growth assays, arsenite significantly stimulated the proliferation of MCF-7 cells compared with cells grown in estrogen-depleted medium. Addition of an antiestrogen blocked growth stimulation by arsenite. In binding assays, arsenite blocked the binding of estradiol to ER (K_i = 5 ± 0.5 nM; n = 3), suggesting that the compound interacts with the hormone-binding domain of the receptor. To determine whether interaction of arsenite with the hormone-binding domain results in receptor activation, COS-1 cells were transiently cotransfected with the chimeric receptors GAL-ER, which contains the hormone-binding domain of ER and the DNA-binding domain of the transcription factor GAL4, and a GAL4-responsive CAT reporter gene. Treatment of cells with estradiol or arsenite resulted in a 4-fold increase in CAT activity. The effects of arsenite on the chimeric receptor were blocked by the antiestrogen, suggesting that arsenite activates ER through an interaction with the hormone-binding domain of the receptor. Transfection assays with ER mutants identified C381, C447, H524, and N532 as interaction sites of arsenite with the hormone-binding domain.

This article has been cited by other articles:

				D. J. Veselik, S. Divekar, S. Dakshanamurthy, G. B. Storchan, J. M.A. Turner, K. L. Graham, L. Huang, A. Stoica, and M. B. Martin Activation of Estrogen Receptor-{alpha} by the Anion Nitrite Cancer Res., May 15, 2008; 68(10): 3950 - 3958. [Abstract] [Full Text] [PDF]

				M. B. Martin, R. Reiter, M. Johnson, M. S. Shah, M. C. Iann, B. Singh, J. K. Richards, A. Wang, and A. Stoica Effects of Tobacco Smoke Condensate on Estrogen Receptor-{alpha} Gene Expression and Activity Endocrinology, October 1, 2007; 148(10): 4676 - 4686. [Abstract] [Full Text] [PDF]

				W. H. Watson and J. D. Yager Arsenic: Extension of its Endocrine Disruption Potential to Interference with Estrogen Receptor-Mediated Signaling Toxicol. Sci., July 1, 2007; 98(1): 1 - 4. [Full Text] [PDF]

				J. C. Davey, J. E. Bodwell, J. A. Gosse, and J. W. Hamilton Arsenic as an Endocrine Disruptor: Effects of Arsenic on Estrogen Receptor-Mediated Gene Expression In Vivo and in Cell Culture Toxicol. Sci., July 1, 2007; 98(1): 75 - 86. [Abstract] [Full Text] [PDF]

				J. Kohrle, F. Jakob, B. Contempre, and J. E. Dumont Selenium, the Thyroid, and the Endocrine System Endocr. Rev., December 1, 2005; 26(7): 944 - 984. [Abstract] [Full Text] [PDF]

				M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]

				J. J. Pinzone, H. Stevenson, J. S. Strobl, and P. E. Berg Molecular and Cellular Determinants of Estrogen Receptor {alpha} Expression Mol. Cell. Biol., June 1, 2004; 24(11): 4605 - 4612. [Full Text] [PDF]

				M. B. Martin, R. Reiter, T. Pham, Y. R. Avellanet, J. Camara, M. Lahm, E. Pentecost, K. Pratap, B. A. Gilmore, S. Divekar, et al. Estrogen-Like Activity of Metals in Mcf-7 Breast Cancer Cells Endocrinology, June 1, 2003; 144(6): 2425 - 2436. [Abstract] [Full Text] [PDF]

				W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman Mechanisms of Action of Arsenic Trioxide Cancer Res., July 15, 2002; 62(14): 3893 - 3903. [Abstract] [Full Text] [PDF]

				E. K. Balcer-Kubiczek, G. H. Harrison, J.-F. Xu, and P. L. Gutierrez Coordinate Late Expression of Trefoil Peptide Genes (pS2/TFF1 and ITF/TFF3) in Human Breast, Colon, and Gastric Tumor Cells Exposed to X-Rays Mol. Cancer Ther., April 1, 2002; 1(6): 405 - 415. [Abstract] [Full Text] [PDF]